NAD+ may be administered more slowly for comfort
Food and Drug Administration (FDA) for medical, diagnostic, or therapeutic use
The peptide exhibits consistent efficacy in models of acute and chronic injury regardless of administration route (intraperitoneal, oral, or local application), a unique characteristic distinguishing it from other growth factors that typically require localized delivery with carrier systems
A., Zukowski, J., Ercal, N., Matthews, R
A common research format is a 100 mg vial reconstituted in 5 mL of bacteriostatic water, giving you 20 mg/mL of GHK-Cu, which corresponds to roughly 51 mM
It also avoids the added risks that come with injections, including sterility, sourcing, dosing, and product purity